Augmenting Pharma Research with Synthetic Respondents

Augmenting Pharma Research with Synthetic Respondents

In this episode of the ProcDNA podcast, Nishant Agarwal, Director of Analytics (ProcDNA), is joined by Rajan Dua, Director of Technology (ProcDNA), to discuss the rapid emergence of synthetic respondents in pharma market research. They explore what’s real versus hype, where synthetic respondents add the most value, and why they are best used to augment, not replace, traditional research. The conversation covers data quality, governance, and validation, along with practical use cases such as faster hypothesis testing, message refinement, and early directional insights for brand teams. Listen in to learn how synthetic respondents can help accelerate decision-making while maintaining trust, transparency, and compliance.

Nishant Agarwal

Director of Analytics

Rajan Dua

Director of Technology

Key Takeaways

Synthetic Respondents Augment, Not Replace

Synthetic respondents are designed to complement traditional research by accelerating early insights, not replacing real HCP or patient engagement.

Speed Enables Better Decisions

Brand and research teams can move from questions to directional insights in days instead of weeks, enabling faster hypothesis testing.

Data Quality is Non-Negotiable

The value of synthetic respondents depends on being grounded in high-quality, disease-specific, real-world research data.

Governance Builds Trust

Clear audit trails and traceability ensure transparency, credibility, and compliance in highly regulated Pharma industry.

Practical Use Cases Matter Most

From message testing to refining discussion guides, synthetic respondents deliver the most value when applied to defined, real-world scenarios.

More Episodes

Partner with us

At the heart of our approach is a commitment to your success. We take time to understand your unique challenges and craft tailored solutions that drive meaningful results. Let’s build something extraordinary together.